{"id":4414,"date":"2025-03-31T18:12:07","date_gmt":"2025-03-31T18:12:07","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/timolol-maleate-txt\/"},"modified":"2025-03-31T18:12:07","modified_gmt":"2025-03-31T18:12:07","slug":"timolol-maleate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/timolol-maleate-txt\/","title":{"rendered":"Timolol maleate.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Beta-adrenoceptor blocker: Hypertension Angina Glaucoma Migraine prophylaxis

DOSE IN NORMAL RENAL FUNCTION <\/H3> Hypertension: 10\u201360 mg daily, doses >30 mg in divided doses Angina: 5\u201330 mg twice daily Post MI: 5\u201310 mg twice daily Migraine:
  • 10 to 20 &nbsp &nbsp : mg daily in 1\u20132 divided doses

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 432.5 <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 10 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 5 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 1.7 <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 4\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Start with lowest dose and titrate according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Start with lowest dose and titrate according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp : Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: NSAIDs antagonise hypotensive effect\n
  • Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone\n
  • Antidepressants: enhanced hypotensive effect with MAOIs Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin\n
  • Antimalarials: increased risk of bradycardia with mefloquine Antipsychotics enhanced hypotensive effect with phenothiazines\n
  • Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil\n
  • Diuretics: enhanced hypotensive effect\n
  • Moxisylyte: possible severe postural hypotension\n
  • Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine Tropisetron: increased risk of ventricular arrhythmias \u2013 use with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral, topical

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> Timolol is more hydrophilic than lipophilic
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Beta-adrenoceptor blocker: Hypertension Angina Glaucoma Migraine prophylaxis DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4414","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4414"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4414\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}